PT  - JOURNAL ARTICLE
AU  - Kevin S O’Connell
AU  - Ida E. Sønderby
AU  - Oleksandr Frei
AU  - Dennis van der Meer
AU  - Lavinia Athanasiu
AU  - Olav B. Smeland
AU  - Dag Alnæs
AU  - Tobias Kaufmann
AU  - Lars T. Westlye
AU  - Vidar M. Steen
AU  - Ole A. Andreassen
AU  - Timothy Hughes
AU  - Srdjan Djurovic
TI  - Association between complement component 4A expression, cognitive performance and brain imaging measures in UK Biobank
AID  - 10.1101/2020.06.05.20122978
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.05.20122978
4099  - http://medrxiv.org/content/early/2020/06/07/2020.06.05.20122978.short
4100  - http://medrxiv.org/content/early/2020/06/07/2020.06.05.20122978.full
AB  - Altered expression of the complement component C4A gene is a known risk factor for schizophrenia. Further, predicted brain C4A expression has also been associated with memory function highlighting that altered C4A expression in the brain may be relevant for cognitive and behavioral traits. We investigated if predicted brain C4A expression was associated with cognitive performance and brain imaging measures in the UK Biobank. We identified significant negative associations between predicted C4A expression and performance on select cognitive tests, and significant associations with MRI-based cortical thickness and surface area in select regions. Finally, we observed significant inconsistent partial mediation of the effects of predicted C4A expression on cognitive performance, by specific brain structure measures. These results demonstrate that the C4 risk locus is associated with the central endophenotypes of cognitive performance and brain morphology, even when considered independently of other genetic risk factors and in individuals without mental or neurological disorders.Competing Interest StatementDr. Andreassen reports personal fees from Lundbeck outside the submitted work. The other authors have no conflicts of interest to declare.Funding StatementWe gratefully acknowledge support from the Research Council of Norway (grant 273291, 248980, 248778 and 248828 for OAA; grant 249795 for LTW), and the South-Eastern Norway Regional Health Authority (grant 2018094 for SD; grant 2020060 for IES; grant 2017-112 for OAA; grant 2019101 for LTW), the European Research Council under the European Union Horizon 2020 research and innovation program (ERC Starting Grant 802998: BRAINMINT for LTW).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The South-Eastern Norway Regional Committees for Medical and Health Research EthicsAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis research has been conducted using the UK Biobank Resource (Application number 27412) https://www.ukbiobank.ac.uk/